Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at delrayresearch.com, will continue to monitor these healthtech companies to see if the momentum continues. DelrayResearch.com is also looking into these tickers DAWN, COGT, RMD, BSX, RACE, RTX..
Recent PTCT Stock Price: $24.28
Summary: PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.
Jeffrey Hung analyst at Morgan Stanley reiterates coverage on PTC Therapeutics (PTCT) stock in the energy sector with a Hold rating and has set PTCT's stock price target at $31.
TipRanks.com reports that PTC Therapeutics currently has 5 analysts offering 12-month price targets on PTCT and the consensus is a Hold rating with an average stock price target of $37.60. The most recent PTCT stock price we have is $24.28 and we are not making any PTCT forecasts at this time.
In addition, TradingView issued a Strong sell rating for PTCT over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on PTCT. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on PTCT, please click here >>
Alnylam Pharma, ALNY
Recent ALNY Stock Price: $179.77
Summary: Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..
Patrick Trucchio analyst at H.C. Wainwright reiterates coverage on Alnylam Pharma (ALNY) stock in the energy sector with a Buy rating and has set ALNY's stock price target at $405.
TipRanks.com reports that Alnylam Pharma currently has 5 analysts offering 12-month price targets on ALNY and the consensus is a Strong Buy rating with an average stock price target of $282.00. The most recent ALNY stock price we have is $179.77 and we are not making any ALNY forecasts at this time.
In addition, TradingView issued a Strong sell rating for ALNY over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALNY. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ALNY, please click here >>
BioMarin Pharmaceutical, BMRN
Recent BMRN Stock Price: $88.60
Summary: BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.
Eliana Merle analyst at UBS reiterates coverage on BioMarin Pharmaceutical (BMRN) stock in the energy sector with a Buy rating and has set BMRN's stock price target at $120.
TipRanks.com reports that BioMarin Pharmaceutical currently has 5 analysts offering 12-month price targets on BMRN and the consensus is a Moderate Buy rating with an average stock price target of $102.80. The most recent BMRN stock price we have is $88.60 and we are not making any BMRN forecasts at this time.
In addition, TradingView issued a sell rating for BMRN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BMRN. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BMRN, please click here >>
Laboratory, LH
Recent LH Stock Price: $201.17
Summary: Laboratory Corporation of America Holdings or LabCorp is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. The provide vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
Eric Coldwell analyst at Robert W. Baird reiterates coverage on Laboratory (LH) stock in the energy sector with a Buy rating and has set LH's stock price target at $237.
TipRanks.com reports that Laboratory currently has 5 analysts offering 12-month price targets on LH and the consensus is a Strong Buy rating with an average stock price target of $242.40. The most recent LH stock price we have is $201.17 and we are not making any LH forecasts at this time.
In addition, TradingView issued a sell rating for LH over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LH. delrayresearch.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on LH, please click here >>
The editors at delrayresearch.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
Click here to join thousands of investors who have already signed up for a free subscription to consumer staples stocks newsletter PoliticsAndMyPortfolio.com.
==============================================================================
